Company news

Pacira BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

September 12, 2022

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

September 6, 2022

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

August 9, 2022

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain

August 8, 2022

Pacira BioSciences Reports Second Quarter 2022 Financial Results

August 2, 2022

Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 1, 2022

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

July 26, 2022

Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million

July 13, 2022

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

June 15, 2022

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022

June 13, 2022

Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference

June 1, 2022

Pacira BioSciences and the National Senior Games Association Break a GUINNESS WORLD RECORDS™ Title for the Largest Game of Freeze Dance

May 24, 2022

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022

May 11, 2022

Pacira BioSciences to Present at Two Healthcare Conferences in May

May 9, 2022

Pacira BioSciences Reports First Quarter 2022 Financial Results

May 3, 2022

Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022

April 26, 2022

Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022

April 11, 2022

Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

April 4, 2022

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022

March 14, 2022

Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference

March 8, 2022

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

February 23, 2022

Pacira to Report 2021 Financial Results on Thursday February 24, 2022

February 15, 2022

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022

February 14, 2022

Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7 Million

January 5, 2022

Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B

December 8, 2021

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021

December 6, 2021

Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

November 22, 2021

Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management

November 18, 2021

Pacira BioSciences to Present at the Jefferies London Healthcare Conference

November 9, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021

November 8, 2021

Pacira Files Lawsuit Against eVenus for Patent Infringement

November 7, 2021

Pacira BioSciences Reports Third Quarter 2021 Financial Results

November 2, 2021

Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition

November 1, 2021

Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021

October 26, 2021

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

October 10, 2021

Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL

October 7, 2021

Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®

October 3, 2021

Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility

September 29, 2021

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

September 20, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021

September 14, 2021

Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 7, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021

August 9, 2021

Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference

August 3, 2021

Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021

August 2, 2021

Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process

August 1, 2021

New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty

July 28, 2021

Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021

July 19, 2021

Pacira Announces EXPAREL Distribution Agreement with Eurofarma in Latin America

June 21, 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021

June 7, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.